




"

We have a simple message to all countries:


test, test, test."

Why do we need diagnostics?



- Testing is essential at every stage of the pandemic response
- Effective diagnostics are essential to limit the spread of infection
- Many countries have shown that "test, trace and isolate" works

How can testing help save lives now? By averting 1 death for every ~1000 tests



1. HCW: Health Care Workers Note: Test rate – tests per 1,000, at two weeks after the 100th confirmed case; Death rate – daily deaths per 1 million as of May 12, shown as a rolling seven-day average; Source: TIME Magazine (Emily Barone, Lon Tweeten, Elijah Wolfson - Our World in Data; FIND COVID-19 test tracker (June 2nd 2020)

Barriers mean we cannot reach everyone who needs a test today

CURRENT TESTING STRATEGIES RELY ON SYSTEMS & INFRASTUCTURE

• Complex, expensive, slow, laboratory-based, resource-intensive

SUPPLY SHORTAGES JEOPARDIZE ACCESS

 Manufacturing capacity is not in place to rapidly scale up production of tests to meet global demand

RAPID DIAGNOSTIC TESTS NEED INNOVATION

• Need faster, more accurate, affordable, easier to use tests

TESTING IN LMICS IS 10% OF WHAT IT IS IN HICS, <1% IN LICS

ACT-A Diagnostics Partnership

FIND Agency for Science, Technology Agency Agency Agency Age

FIND (co-convenor)

DEVELOPING COUNTR NGO DELEGATION GLOBAL FUND TO FIGHT AIDS, TB & MALAR

• Academia

Industry
Regulators
CSOs

Northeastern

₩НО

- Funders
- International
- organizations
- Country reps^FQR

Afrocab Treatment Access Partnership

L& MELINDA GATES foundation OUR GOAL

WORLD BANK GROUP



To drive universal and equitable access to diagnostics as per WHA resolution

HOW WE ARE HELPING

Pan American Health Organization

R&D - Supporting R&D^{avation in Global H}

Market Readiness - Engaging in market-shaping Mayo CLINIC interventions to stimulate rapid, massive scale-up for International Supply - Powering supply and distribution, with additional support for LMICs

Country Readiness - Building the capacity of countries' Europe health infrastructures to enable uptake of the tests

GATE

AdvaMedDx Vital Insights | Transforming

What do we want to deliver in next 12 months?

	R&D	Well-performing Ag RDTs & point-of-care molecular tests developed		
The second secon		Non-proprietary test result reader app and interoperability solution developed		All countries able to deploy affordable , quality POC tests
Re	Market eadiness	Regionalized production incl. in LMICs & mechanism set up to make RDTs affordable and available		
	Supply	500m tests procured		Significant number of LMICs have been supported to put in place effective test, trace, isolate strategies
Countr Preparednes	Country	Country policies and uptake in integrated testing strategies driven in 50+ countries		
		10,000 health care workers trained		Disruption of core health services minimized

۰.

Meeting these milestones will require total of \$6B and closing existing funding gaps

Focus area	\$needs in M		
R&D	300 → 1	4%	86%
Market Readiness	100 → 1	2%	88%
Supply	5,000 → 3%	0	97%
Country Preparedness	$600 \rightarrow 3\%$	0	97%
Total immediate need	6,000 \$	funded	\$ Gap

By closing the urgent funding gaps, Member States can benefit from...

Global investments in R&D and market interventions to create competitive markets that will make tests more accessible and affordable for all countries

Stronger country testing capacity and development of testing strategies

Support for selecting the best tests for local needs


Preventing the procurement of low quality or fake tests

Well-performing innovative tests brought to market


Ability to scale procurement of existing PCR and new RDT tests

Making informed decisions about pandemic control measures and when lockdowns can be eased, and economies re-opened

What have we achieved in the past 8 weeks?



Dx Consortium has already procured more than 6m tests



ECA

Allocation framework for LMICs

ACTaccelerator

ACCESS TO COVID-19 TOOLS

Key innovations underway to address point of care testing and scalability

Manufacturing innovations


Advanced semi-conductor based microfluidics Scalable manufacturing for Low cost products

Business model innovations

Local-manufacturing and improved distribution Enhanced connectivity for data transmission Link to payment /insurance services

Multi-modality capabilities

Multiplex different targets; e.g. Covid and Flu Platform approach: Integration of multiple platforms, Combined immuno- and molecular assays



Technology breakthroughs


Improved reagents, e.g new antibodies More sensitive readouts, e.g. new particles Next generation technologies- e.g. Crispr-based Enhanced digital integration

Innovations in usability

Instrument-free, handheld, portable systems Decentralized testing for pharmacy or athome use

Testing is vital to both mitigating direct impact of COVID-19 and minimizing knock-on impact


We risk facing future bottlenecks when it is time to roll out approved therapeutics and vaccines



If insufficient testing capacity

+ Need for differential testing

And we will lose ground on global health gains over past 20 years



Source: Imperial College London. www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-19-hiv-tb-malaria/ (accessed 3 June 2020)

In summary

Over the next 12 months, we need \$6 billion to procure and deploy 500 million tests in countries that might otherwise miss out

The world must seize a window of opportunity and put in place the right conditions for large-scale testing strategies now

Every dollar invested in testing today is a dollar invested in our future global health security and an opportunity to protect the health advances of recent decades



#UnitedAgainstCoronavirus

#StrongerTogether | #GlobalResponse | #GlobalGoalUnite

STheGlobalFund

Organization Because diagnosis matters